Anika Therapeutics Hits New 52-Week High at $22.32

Anika Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 22.32 on August 21, 2026. This achievement marks a notable increase from its 52-week low of USD 8.37, reflecting a substantial upward movement in the stock's performance over the past year. Despite this recent high, Anika Therapeutics has experienced a 1-year performance decline of 15.29%, contrasting sharply with the S&P 500's gain of 20.47% during the same period. The company's market capitalization stands at USD 191 million, indicating its microcap status within the industry. Financial metrics reveal that Anika Therapeutics is currently loss-making, with a negative return on equity of -6.96% and a debt-to-equity ratio of -0.39. The stock does not offer a dividend yield, and its price-to-book ratio is 1.33. As the company continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this new price milestone highlights its current market position.